Quoin reports positive Phase 2 data for QRX003 in Netherton Syndrome; cash $14M

Quoin Pharmaceuticals, Ltd.

Five of six evaluable subjects showed negligible/absent pruritus after QRX003 treatment in open-label study.
All six subjects improved in Investigator skin scoring; favorable patient global assessment across metrics.
No safety concerns in either ongoing study; protocol amendments planned: eliminate lower 2% dose, twice-daily dosing.
Cash, equivalents and marketable securities $14.0M as of Sept 30, 2023; runway expected through end of 2024.
Net loss $2.1M for Q3 2023 vs $2.3M for Q3 2022; nine-month net loss $7.2M flat year-over-year.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Quoin Pharmaceuticals, Ltd. reported the quarter ended September 30, 2023 results: net income approximately $2.1 million.

Period: the quarter ended September 30, 2023
Net income: approximately $2.1 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023 was approximately $2.1 million compared to approximately $2.3 million for the quarter ended September 30, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-23-116370

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.